spacer
home > pmps > autumn 2008 > the future’s bright
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Future’s Bright

How do you think your sector has developed over the past 10 years?

Temperature controlled packaging has become a defined sector in the last 10 years, driven by the increasing use of biological products in the healthcare sector, such as erythropoietins for the treatment of anaemia and beta interferons for multiple sclerosis, anti-inflammatories and cancer treatments. These largely protein-based products are highly sensitive to temperature, requiring careful storage and distribution in order to be effective. The range from +2 to +8°C is such a prevalent specification that it has become a de facto standard. Other temperature requirements have since emerged, most notably temperate (+15 to +25 or +30°C). Regulatory awareness, notably that of the US FDA and the UK’s MHRA, and industry practice in the form of GxPs have kept pace with these demands, as has an array of shipping technologies, both passive and active.

What would you perceive as the biggest challenges facing the industry over the next 10 years?

The challenge now is to harmonise standards across an increasingly global platform. Industrial and international cooperation...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Tim Jennings is a Director of the French company Emball’iso SA and of two of its international affiliates. He has 10 years’ experience in the shipping of temperature sensitive products at two of the leading European companies in the field. Prior to these commercial roles Tim worked in the supply of engineering design and consultancy services to the pharmaceutical and petrochemical industries, specialising in ion exchange and adsorbent processes. Tim has a BSc (Hons) in Materials Technology.
spacer
Tim Jennings
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University.
More info >>

White Papers

Environmental Factors in Data Centres

Dycem

In addition to temperature and humidity, there are many more constraints in the environment that increase failure rates, explains Emilio Sapiña of Secure Techincal Rooms.
More info >>

 
Industry Events

SMi Presents the 4th Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)

11-13 May 2020, Copthorne Tara Hotel, London, UK

Announcement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement